Oncology Research Editorial Office

Oncology Research, Vol.32, No.11, pp. 1827-1827, 2024, DOI:10.32604/or.2024.056902 - 16 October 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.11, pp. 1815-1815, 2024, DOI:10.32604/or.2024.056890 - 16 October 2024

Abstract This article has no abstract. More >

LICHEN XU^1,2, PAN ZHANG^3,*, GUIQI ZHANG², ZHAOLIANG SHEN⁴, XIZHUANG BAI^1,3,*

Oncology Research, Vol.32, No.11, pp. 1777-1789, 2024, DOI:10.32604/or.2024.047704 - 16 October 2024

Abstract Background: Osteosarcoma (OS), recognized as the predominant malignant tumor originating from bones, necessitates an in-depth comprehension of its intrinsic mechanisms to pinpoint novel therapeutic targets and enhance treatment methodologies. The role of fat mass and obesity-associated (FTO) in OS, particularly its correlation with malignant traits, and the fundamental mechanism, remains to be elucidated. Materials and Methods: 1. The FTO expression and survival rate in tumors were analyzed. 2. FTO in OS cell lines was quantified utilizing western blot and PCR. 3. FTO was upregulated and downregulated separately in MG63. 4. The impact of FTO on the… More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.10, pp. 1697-1698, 2024, DOI:10.32604/or.2024.056918 - 18 September 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.10, pp. 1677-1678, 2024, DOI:10.32604/or.2024.056891 - 18 September 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.9, pp. 1541-1541, 2024, DOI:10.32604/or.2024.056127 - 23 August 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.9, pp. 1527-1527, 2024, DOI:10.32604/or.2024.056120 - 23 August 2024

Abstract This article has no abstract. More >

Oncology Research Editorial Office

Oncology Research, Vol.32, No.9, pp. 1523-1523, 2024, DOI:10.32604/or.2024.056118 - 23 August 2024

Abstract This article has no abstract. More >

PEILING WU^#, LIFANG ZHAO^#, HONGYAN ZHANG, YUEYAN LOU, DONGFANG CHEN, SHAN XUE, XUEQING LIU^*, HANDONG JIANG^*

Oncology Research, Vol.32, No.9, pp. 1439-1452, 2024, DOI:10.32604/or.2024.047490 - 23 August 2024

Abstract Objectives: The pro-oncogenic effects of NCAPD2 have been extensively studied across various tumor types; however, its precise role within the context of lung adenocarcinoma (LUAD) remains elusive. This study aims to elucidate the biological functions of NCAPD2 in LUAD and unravel the underlying mechanistic pathways. Methods: Utilizing bioinformatics methodologies, we explored the differential expression of NCAPD2 between normal and tumor samples, along with its correlations with clinical-pathological characteristics, survival prognosis, and immune infiltration. Results: In the TCGA-LUAD dataset, tumor samples demonstrated significantly elevated levels of NCAPD2 expression compared to normal samples (p < 0.001). Clinically, higher… More >

LIANG HE^1,2, WEI HAN^1,3, KAI YUE¹, XUDONG WANG^1,*

Oncology Research, Vol.32, No.9, pp. 1467-1478, 2024, DOI:10.32604/or.2024.047382 - 23 August 2024

Abstract Objectives: Thyroid cancer (THCA) is the most common malignant tumor in endocrine system and the incidence has been increasing worldwide. And the number of patients dying from THCA has also gradually risen because the incidence continues to increase, so the mechanisms related to effective targets is necessary to improve the survival. This study was to preliminarily investigate the effects of the COL4A2 gene on the regulation of thyroid cancer (THCA) cell proliferation and the associated pathways. Methods: Bioinformatics analysis revealed that COL4A2 was closely associated with cancer development. COL4A2 expression in THCA tissues was analyzed… More >